ACP
AIMT

Acuta Capital Partners’s Aimmune Therapeutics AIMT Stock Holding History

Acuta Capital Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-58,525
Closed -$1.45M – 91
2017
Q3 		$1.45M Buy
+58,525
New +$1.26M 0.26% 45

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acuta Capital Partners's AIMT Position: Q4 2017 in Review

Acuta Capital Partners sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 58,525 shares — an estimated $1.45M sold.

Acuta Capital Partners first reported a position in AIMT in Q3 2017 and held it in 1 quarter. The position peaked at $1.45M in Q3 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • Acuta Capital Partners reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 58,525 Aimmune Therapeutics shares in Q4 2017, an estimated $1.45M.
  • Acuta Capital Partners first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 1 quarter.
  • Acuta Capital Partners's Aimmune Therapeutics position peaked at $1.45M in Q3 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.